RCS - Genflow Biosciences - Strategic Technology Collaboration

Genflow BiosciencesAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260420:nRST0897Ba&default-theme=true

RNS Number : 0897B  Genflow Biosciences PLC  20 April 2026

 

Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas
Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery
Platform

Genflow Biosciences Plc (LSE: GENF | OTCQB: GENFF) ("Genflow" or the
"Company"), a European biotechnology company focused on the development of
gene therapies for age-related diseases, today announces that it has entered
into a strategic technology collaboration with Acuitas Therapeutics
("Acuitas"), a globally recognised leader in lipid nanoparticle ("LNP")
delivery systems whose technology has underpinned some of the most
commercially successful mRNA therapeutic programmes brought to market to date.

Strategic Significance

The Board considers this collaboration to represent a material step forward in
the advancement of the Company's SIRT6 platform. Acuitas' LNP technology is
among the most clinically and commercially validated delivery platforms in the
mRNA therapeutics industry, and the Company's ability to access this
capability on a fully funded basis reflects the external confidence in
Genflow's proprietary science.

The collaboration will enable Genflow to evaluate the integration of LNP-based
delivery with its SIRT6 mRNA payload across a newly initiated development
programme, with the objective of generating preclinical data to support future
clinical and commercial development decisions.

Terms of the Collaboration

Under the agreement, Genflow will provide its proprietary SIRT6 mRNA payload
to Acuitas, which will formulate the payload using its proprietary LNP
platform. The resulting formulations will be returned to Genflow for use in
preclinical evaluation studies.

The collaboration is fully funded by Acuitas. There is no cash consideration
payable by Genflow, and the arrangement is entirely non-dilutive to existing
shareholders. The Company does not expect the collaboration to have a material
impact on near-term revenues.

While the current agreement is focused on initial preclinical evaluation
activities, it establishes a formal framework for potential further
development and strategic engagement between the parties, subject to the
outcome of the ongoing work.

About Acuitas Therapeutics

Acuitas is a privately held biopharmaceutical company headquartered in
Vancouver, Canada, and is one of the foremost specialists in the development
and licensing of LNP technology for mRNA-based therapeutics. Acuitas' LNP
platform has been incorporated into multiple landmark mRNA programmes that
have achieved both regulatory approval and large-scale commercial success,
establishing Acuitas as a pre-eminent partner of choice for leading
organisations advancing mRNA medicines globally.

The Board regards Acuitas' decision to invest its own resources in formulating
Genflow's SIRT6 mRNA payload as a meaningful and independent validation of the
quality and potential of the Company's proprietary technology.

Outlook and Commercial Potential

The data generated through this collaboration are expected to inform key
future development decisions, including delivery optimisation, target tissue
engagement, and the structuring of potential partnering and licensing
arrangements with third parties. The Company's SIRT6 platform addresses
mechanisms of fundamental importance to age-related disease, and the addition
of an optimised LNP delivery modality is expected to materially broaden the
scope and commercial attractiveness of the programme.

The Company will provide further updates on the progress of this collaboration
as developments warrant and in accordance with its obligations under the
Market Abuse Regulation.

Eric Leire, Chief Executive Officer of Genflow Biosciences, commented:

"This collaboration with Acuitas is, in our view, one of the most significant
steps we have taken in the development of our SIRT6 platform to date. Acuitas
are the gold standard in LNP delivery - their technology has already
transformed modern medicine - and the fact that they are committing their own
resources to work with our science is a powerful endorsement of what we are
building. For our shareholders, the headline facts are straightforward: we are
gaining access to world-class, clinically proven delivery technology at no
cost and with no dilution. This is precisely the kind of capital-efficient,
high-impact collaboration that de-risks our pipeline, strengthens our
partnering position, and accelerates our path towards clinical development. We
look forward to sharing further updates as this programme advances."

 

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32 477495 881       +1 475 477 9401
                      Jonathan@Harbor-Access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies for age-related diseases, with the goal
of promoting longer and healthier lives while mitigating the financial,
emotional, and social impacts of a fast-growing aging global population.
Genflow's lead compound, GF-1002, works through the delivery of a centenarian
variant of the SIRT6 gene which has yielded promising preclinical results.
Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian
gene therapy in aged dogs began in March 2025. Other programs include a
clinical trial that will explore the potential benefits of GF-1002 in treating
MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent
chronic liver disease for which there is no effective treatments. Please visit
www.genflowbio.com (http://www.genflowbio.com)   and follow the Company on
LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

DISCLAIMER

 

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

 

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

 

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

 

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFETSEIALIR



            Copyright 2019 Regulatory News Service, all rights reserved